se gb

Athera presents at the first International Pharmacy Engineering and Biotechnology Forum in St. Petersburg

St. Petersburg, Russia, 28 April 2011 – Athera CEO Carina Schmidt is one of the invited speakers at the first international business forum IPhEB, dedicated to establishment of a pharmaceutical cluster in St. Petersburg. Ms Schmidt will build on experiences from development of the emerging biotech company Athera, part of Karolinska Development AB (publ) portfolio- from early innovation stages to product development and commercialization - to discuss issues around the topic “From Innovation to Business – Challenges and Rewards”. The IPhEB business event is planned to be participated by over 300 delegates from 200 companies – government authorities, top managers and experts of the Russian and international pharmaceutical and biotechnological enterprises, and representatives of scientific research centers and institutes. Speakers include Evgeny Zaytsev, Director General, Helix  Ventures, Dr. Jonas Brambeck, Investment Manager Industrifonden, Dr. Bo-Ragnar Tolf, Director, Innovation Office, Karolinska Institutet, G. Steven Burrill, Director General, Burrill & Company and many other leading specialists of the industry.

About Athera Biotechnologies AB (publ)
Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.

PC-mAb from Athera is currently in pre-clinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome.

In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics.

Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio. www.athera.se

For further Information:

Athera Biotechnologies AB (publ)
Chief Executive Officer

Carina Schmidt

Tel +46 761938190
c.schmidt@athera.se

2011-04-28